GPhA Makes Spreadsheet Case For Patent Settlements After Legal Loss
Executive Summary
IMS report finds that 33 drugs launched prior to patent expiry as a result of patent settlements reduced drug costs by $25.5 billion from 2005 to 2012. But the selection of which settlements to calculate the savings from reveals the fundamental difference in perspectives between industry and FTC that remain in the wake of the Supreme Court ruling.
You may also be interested in...
FDA May Drop Generic Liability Shield, Allow ANDA Manufacturers To Change Labels
Solicitor General notes that FDA is considering changing its regulations in an amicus brief in Mutual Pharmaceutical v. Bartlett; government says design defect claims against generic manufacturers are preempted by federal law in the case at hand but may be brought in other situations.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.